ES2159528T3 - Amantadina y compuestos asociados para su utilizacion en el tratamiento de la neuropatia periferica dolorosa. - Google Patents

Amantadina y compuestos asociados para su utilizacion en el tratamiento de la neuropatia periferica dolorosa.

Info

Publication number
ES2159528T3
ES2159528T3 ES93921355T ES93921355T ES2159528T3 ES 2159528 T3 ES2159528 T3 ES 2159528T3 ES 93921355 T ES93921355 T ES 93921355T ES 93921355 T ES93921355 T ES 93921355T ES 2159528 T3 ES2159528 T3 ES 2159528T3
Authority
ES
Spain
Prior art keywords
amantadine
treatment
peripheral neuropathy
associated compounds
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921355T
Other languages
English (en)
Inventor
Stuart A Lipton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Application granted granted Critical
Publication of ES2159528T3 publication Critical patent/ES2159528T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBE UN METODO PARA REDUCIR DAÑO NEURONAL MEDIANTE RECEPTOR DE NMDA EN UN MAMIFERO ADMINISTRANDO AL MAMIFERO UN COMPUESTO DE LA FORMULA MOSTRADA EN FIG. 1 (O UNA SAL DE ELLA FISIOLOGICAMENTE ACEPTABLE), EN DONDE R1 INCLUYE UN GRUPO AMINO, R2-R17 SON INDEPENDIENTEMENTE H O UN GRUPO DE CADENA ALIFATICA CORTA QUE COMPRENDE DE 1-5 CARBONOS, Y R4 Y R10 TAMBIEN PUEDEN (INDEPENDIENTEMENTE) SER HALOGENO O UN GRUPO ACILO. TAMBIEN SE DESCRIBE UN FILTRO PARA ANTAGONISTAS DE RECEPTOR NMDA QUE MEDIA NEUROTOXICIDAD EL CUAL TIENE UNA PERSPECTIVA MEJORADA SIENDO CLINICAMENTE TOLERADO Y SELECTIVO CONTRA TAL NEUROTOXICIDAD.
ES93921355T 1992-09-03 1993-09-03 Amantadina y compuestos asociados para su utilizacion en el tratamiento de la neuropatia periferica dolorosa. Expired - Lifetime ES2159528T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/939,824 US5334618A (en) 1991-04-04 1992-09-03 Method of preventing NMDA receptor-mediated neuronal damage

Publications (1)

Publication Number Publication Date
ES2159528T3 true ES2159528T3 (es) 2001-10-16

Family

ID=25473800

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921355T Expired - Lifetime ES2159528T3 (es) 1992-09-03 1993-09-03 Amantadina y compuestos asociados para su utilizacion en el tratamiento de la neuropatia periferica dolorosa.

Country Status (12)

Country Link
US (1) US5334618A (es)
EP (1) EP0660707B1 (es)
JP (2) JPH08501297A (es)
AT (1) ATE202474T1 (es)
AU (1) AU4847693A (es)
CA (1) CA2143752C (es)
DE (1) DE69330387T2 (es)
DK (1) DK0660707T3 (es)
ES (1) ES2159528T3 (es)
GR (1) GR3036657T3 (es)
PT (1) PT660707E (es)
WO (1) WO1994005275A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
US6025369A (en) * 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US20060167114A1 (en) * 1998-03-09 2006-07-27 Louis Shuster Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US20070197651A1 (en) * 1998-03-09 2007-08-23 Tufts University Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
GB9901691D0 (en) * 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
EP1190708A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Medical use of substances
EP1190711A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivatives
EP1201234A3 (en) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivates
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2003020257A2 (de) * 2001-08-29 2003-03-13 Eucro European Contract Research Gmbh & Co. Kg VERWENDUNG VON β-ADRENOZEPTOR-AGONISTEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
GB0202161D0 (en) * 2002-01-30 2002-03-20 Vernalis Res Ltd Chemical compounds V
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US20050148673A1 (en) * 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
DK1703902T3 (da) * 2004-01-05 2011-02-14 Merz Pharma Gmbh & Co Kgaa Memantin til behandling af mild til moderat Alzheimer's sygdom
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP1765287A2 (en) 2004-06-17 2007-03-28 Merz Pharma GmbH & Co. KGaA Immediate release formulations of memantine oral dosage forms
MXPA06014587A (es) * 2004-06-17 2007-04-27 Forest Laboratories Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CN100351225C (zh) * 2004-10-28 2007-11-28 中国医学科学院医药生物技术研究所 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用
EP1827385B1 (en) 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20080009546A1 (en) * 2005-05-06 2008-01-10 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
AU2006259619A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
MX2012008514A (es) 2010-01-27 2012-08-17 Takeda Pharmaceutical Compuesto para suministrar transtorno de nervio periferico inducido por agente anticancerigeno.
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US11447442B2 (en) 2017-11-22 2022-09-20 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat CNS disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3456057A (en) * 1968-06-28 1969-07-15 Du Pont Pharmaceutical compositions and methods utilizing 3-aminotricyclo(4.3.1.1**3.8)undecanes
CH603545A5 (es) * 1972-04-20 1978-08-31 Merz & Co
IL53441A0 (en) * 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4148896A (en) * 1978-02-22 1979-04-10 E. I. Du Pont De Nemours And Company Antidepressant combination
US4351847A (en) * 1981-06-26 1982-09-28 Pennwalt Corporation Antiviral alpha, alpha-dialkyl adamantylethylamines
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
US4837218A (en) * 1987-10-23 1989-06-06 Washington University Alkylated bicycloalkaneamines for treatment of neurotoxic injury
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
DE3940410A1 (de) * 1989-12-04 1991-06-06 Schering Ag Neue verwendung von nmda-rezeptor-antagonisten
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids

Also Published As

Publication number Publication date
CA2143752C (en) 2008-11-18
DE69330387T2 (de) 2002-05-16
DE69330387D1 (de) 2001-08-02
ATE202474T1 (de) 2001-07-15
WO1994005275A1 (en) 1994-03-17
PT660707E (pt) 2001-11-30
DK0660707T3 (da) 2001-10-01
EP0660707B1 (en) 2001-06-27
EP0660707A4 (en) 1998-05-13
EP0660707A1 (en) 1995-07-05
US5334618A (en) 1994-08-02
JP2006077034A (ja) 2006-03-23
AU4847693A (en) 1994-03-29
JPH08501297A (ja) 1996-02-13
CA2143752A1 (en) 1994-03-17
GR3036657T3 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
ES2159528T3 (es) Amantadina y compuestos asociados para su utilizacion en el tratamiento de la neuropatia periferica dolorosa.
DK0495776T3 (da) Stabiliserende nitrogenoxid/primær amin-komplekser, der er anvendelige som cardiovaskulære midler
ES2067589T3 (es) Derivados de amidas de aminoacidos.
KR960007545A (ko) 합성 흥분성 아미노산
UA27224C2 (uk) Арилалкіламіни, спосіб їх одержання та фармацевтична композиція
ES2139079T3 (es) Compuestos inmunosupresores y antialergicos, tales como n-(3-oxohexanoil)-homoserina-lactona.
DE69610627D1 (de) Neuartige peptidderivate
PL285248A1 (en) Method of obtaining novel aminophenol derivatives
NO976074D0 (no) To- og treverdige småmolekylinhibitorer for selektin
MY131641A (en) Indoline derivatives, process of preparation and use
IL126110A0 (en) Use of aryl n-substituted carboxamides to kill tumors and novel compounds for such use
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
NO952828L (no) Synergiserende blanding med en antagonist-virkning på NK1- og NK2-reseptorer
FI94354C (fi) Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
GR3036159T3 (en) New compounds and compositions useful as antifungal and antimycobacterial agents.
YU5893A (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
FI925260A (fi) Menetelmä terapeuttisesti käyttökelpoisten 6-amino-substituoitujen oktahydro-1,7,8-indolitsiinitriolijohdannaisten valmistamiseksi
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
ES2060405T3 (es) Derivado de la melatonina que tiene actividad terapeutica en dermatologia.
NZ222045A (en) From diamides up to tetrapeptides for use as anticanvulsants
ES2081144T3 (es) Amidas de aminoacidos substituidas.
DE59207900D1 (de) Iloprost mit wirkung gegen cerebrale malaria
ES2096099T3 (es) Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
GR1001309B (el) Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 660707

Country of ref document: ES